LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 26 of 66
Next
>>
>
626 to 650 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Alpelisib	180619_MC_11	9344	0.0305	108	180	5	13	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_5	288	0.0299	635.9	71.1	15071	356.7	0.0231	0.00683	0.8012
Alpelisib	180619_MC_11	8747	0.0260	91	139	11	6	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_6	230	0.0256	635.9	71.1	15071	356.7	0.0231	0.00255	0.7754
Alpelisib	180619_MC_12	10259	0.0293	122	182	4	12	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_7	304	0.0288	635.9	71.1	15071	356.7	0.0231	0.00571	0.8385
Alpelisib	180619_MC_12	9617	0.0281	129	145	5	11	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_8	274	0.0277	635.9	71.1	15071	356.7	0.0231	0.00463	0.8126
Alpelisib	180619_MC_12	9429	0.0290	135	142	7	18	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_9	277	0.0285	635.9	71.1	15071	356.7	0.0231	0.00546	0.8048
Alpelisib	180619_MC_10	7146	0.0246	77	101	6	13	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_1	178	0.0243	635.9	71.1	15071	356.7	0.0231	0.00123	0.6985
Alpelisib	180619_MC_10	5876	0.0313	90	97	8	7	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_2	187	0.0308	635.9	71.1	15071	356.7	0.0231	0.00777	0.6273
Alpelisib	180619_MC_10	5796	0.0287	84	85	10	5	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_3	169	0.0283	635.9	71.1	15071	356.7	0.0231	0.00526	0.6224
Alpelisib	180619_MC_11	6873	0.0252	79	96	8	4	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_4	175	0.0248	635.9	71.1	15071	356.7	0.0231	0.00176	0.6841
Alpelisib	180619_MC_11	6772	0.0258	87	90	10	13	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_5	177	0.0255	635.9	71.1	15071	356.7	0.0231	0.00240	0.6786
Alpelisib	180619_MC_11	6423	0.0294	64	127	11	21	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_6	191	0.0289	635.9	71.1	15071	356.7	0.0231	0.00580	0.6593
Alpelisib	180619_MC_12	6622	0.0326	103	116	5	19	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_7	219	0.0320	635.9	71.1	15071	356.7	0.0231	0.00894	0.6704
Alpelisib	180619_MC_12	7480	0.0272	103	103	10	10	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_8	206	0.0268	635.9	71.1	15071	356.7	0.0231	0.00373	0.7156
Alpelisib	180619_MC_12	7313	0.0337	105	145	14	21	Alpelisib	3.193598006	treatment	72	2	MCF10A-GM_9	250	0.0331	635.9	71.1	15071	356.7	0.0231	0.00998	0.7071
Alpelisib	180619_MC_10	2802	0.0496	79	64	8	17	Alpelisib	9.98	treatment	72	2	MCF10A-GM_1	143	0.0486	635.9	71.1	15071	356.7	0.0231	0.02548	0.3837
Alpelisib	180619_MC_10	2495	0.0662	103	69	9	4	Alpelisib	9.98	treatment	72	2	MCF10A-GM_2	172	0.0645	635.9	71.1	15071	356.7	0.0231	0.04142	0.3490
Alpelisib	180619_MC_10	2461	0.0458	72	44	12	19	Alpelisib	9.98	treatment	72	2	MCF10A-GM_3	116	0.0450	635.9	71.1	15071	356.7	0.0231	0.02194	0.3449
Alpelisib	180619_MC_11	3250	0.0580	128	68	3	11	Alpelisib	9.98	treatment	72	2	MCF10A-GM_4	196	0.0569	635.9	71.1	15071	356.7	0.0231	0.03380	0.4294
Alpelisib	180619_MC_11	2834	0.0500	84	62	5	22	Alpelisib	9.98	treatment	72	2	MCF10A-GM_5	146	0.0490	635.9	71.1	15071	356.7	0.0231	0.02592	0.3871
Alpelisib	180619_MC_11	3311	0.0342	54	61	6	16	Alpelisib	9.98	treatment	72	2	MCF10A-GM_6	115	0.0336	635.9	71.1	15071	356.7	0.0231	0.01049	0.4352
Alpelisib	180619_MC_12	3314	0.0652	138	87	9	22	Alpelisib	9.98	treatment	72	2	MCF10A-GM_7	225	0.0636	635.9	71.1	15071	356.7	0.0231	0.04050	0.4355
Alpelisib	180619_MC_12	3600	0.0400	76	71	10	14	Alpelisib	9.98	treatment	72	2	MCF10A-GM_8	147	0.0392	635.9	71.1	15071	356.7	0.0231	0.01616	0.4617
Alpelisib	180619_MC_12	3723	0.0499	102	89	14	14	Alpelisib	9.98	treatment	72	2	MCF10A-GM_9	191	0.0488	635.9	71.1	15071	356.7	0.0231	0.02572	0.4725
Dasatinib	180619_MC_10	13415	0.0279	85	291	3	3	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_1	376	0.0273	635.9	71.1	15071	356.7	0.0231	0.00419	0.9497
Dasatinib	180619_MC_10	12996	0.0232	84	219	10	17	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_2	303	0.0228	635.9	71.1	15071	356.7	0.0231	-0.00029	0.9362

|<
<<
Previous
Page 26 of 66
Next
>>
>
626 to 650 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)